Iloperidone Iloperidone selectively binds  to targeted receptors  Neurotransmitters Dopamine  receptor Serotonin receptor Iloperidone Treating Schizophrenia Indication(s) Preclinical Phase 1 Phase 2 Phase 3 Schizophrenia, Psychosis Iloperidone Seven Phase III studies completed to date support the potential therapeutic profile of iloperidone for the treatment of schizophrenia, without some of the major side effects associated with other antipsychotics such as weight gain and movement disorders. Iloperidone’s activity profile can be attributed to its unique structure, which selectively binds to the serotonin and dopamine receptors important for controlling schizophrenic symptoms, without major activity at receptors associated with some troubling side effects. Novartis Pharma AG, Titan’s corporate partner for the development of iloperidone, is completing additional safety testing to more fully profile iloperidone. If the results of these studies are favorable, additional pivotal testing will be performed. Five